Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 20
- Registration Number
- NCT05583071
- Locations
- 🇩🇪
University of Cologne, Cologne, Germany
A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT05579769
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
- Conditions
- Interventions
- Procedure: Surgical resectionOther: Educational and Media InterventionOther: SOC, Educational and Media InterventionProcedure: Ommaya/VPSDrug: MethotrexateDrug: CisplatinDrug: VincristineDrug: CyclophosphamideDrug: CarboplatinDrug: TopotecanDrug: PegfilgrastimDrug: EtoposideDrug: FilgrastimRadiation: Irradiation
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05535166
- Locations
- 🇺🇸
Primary Children's Hospital, Salt Lake City, Utah, United States
🇺🇸Lucille Packard Children's Hospital at Stanford University, Palo Alto, California, United States
🇺🇸Orlando Health Arnold Palmer Hospital for Children, Orlando, Florida, United States
MAD Study of IA-14069
- Conditions
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- ILAb Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT05533372
- Locations
- 🇺🇸
ICON plc., Lenexa, Kansas, United States
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05519579
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
Modified Zhiwang Decoction Combined With Methotrexate in the Treatment of Early Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Beijing University of Chinese Medicine
- Target Recruit Count
- 150
- Registration Number
- NCT05508815
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
- Conditions
- Interventions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 5
- Registration Number
- NCT05494593
- Locations
- 🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
🇺🇸Phoenix Childrens Hospital, Phoenix, Arizona, United States
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 54
- Registration Number
- NCT05476770
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Orange County, Orange, California, United States
🇺🇸UCSF School of Medicine, San Francisco, California, United States
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationDrug: BusulfanDrug: CyclophosphamideProcedure: EchocardiographyDrug: FludarabineProcedure: Haploidentical Hematopoietic Cell TransplantationBiological: Lapine T-Lymphocyte Immune GlobulinProcedure: Matched Unrelated Donor Hematopoietic Cell TransplantationProcedure: Lumbar PunctureDrug: MelphalanDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: Mycophenolate MofetilProcedure: Myeloablative ConditioningOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationBiological: RituximabProcedure: T-Cell Depletion TherapyRadiation: Total-Body IrradiationDrug: TacrolimusDrug: Thiotepa
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 435
- Registration Number
- NCT05457556
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT05445440
- Locations
- 🇺🇸
Quotient Sciences Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.